Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

notoxin that targets the erbB2 receptor.
Clin Cancer Res 5: 2311±5.
112 Benhar I, Pastan I (1995) Characterization
of B1(Fv)PE38 and B1(dsFv)PE38:
single-chain and disulfide-stabilized Fv±
immunotoxins with increased activity
that cause complete remissions of established
human carcinoma xenografts in
nude mice. Clin Cancer Res 1: 1023±9.
113 Lorimer IA, Keppler-Hafkemeyer A,
Beers RA, Pegram CN, Bigner DD,
Pastan I (1996) Recombinant immunotoxins
specific for a mutant epidermal
growth factor receptor: targeting with a
single chain antibody variable domain
isolated by phage display. Proc Natl
Acad Sci USA 93: 14815±20.
114 Chowdhury PS,Viner JL, Beers R, Pastan
I (1998) Isolation of a high-affinity
stable single-chain Fv specific for mesothelin
from DNA-immunized mice
by phage display and construction of a
recombinant immunotoxin with antitumor
activity. Proc Natl Acad Sci USA
95: 669±74.
115 Laske DW, Muraszko KM, Oldfield
EH, et al. (1997) Intraventricular immunotoxin
therapy for leptomeningeal
neoplasia. Neurosurgery 41: 1039±49.
116 Greenfield L, Johnson VG,Youle RJ
(1987) Mutations in diphtheria toxin separate
binding from entry and amplify
immunotoxin selectivity. Science 238:
536±9.
117 Laske DW,Youle RJ, Oldfield EH
(1997) Tumor regression with regional
distribution of the targeted toxin TF-
CRM1 07 in patients with malignant
brain tumors. Nat Med 3: 1362±8.
118 Puri RK, Leland P, Kreilman RJ, Paslan
I (1994) Human neurological cancer
cells express interleukin-4 (IL-4) receptors
which are targets for the toxic
effects of IL-4±Pseudomonas exotoxin
chimeric protein. Int J Cancer 58. 574±
81.
119 Kreitman RJ, Puri RK, Paslan I
(1994) A circularly permuted recombinant
interleukin 4 toxin with increased
activity. Proc Natl Acad Sci USA 91:
6889±93.
120 Kreitman RJ, Pastan I (1995) Targeting
Pseudomonas exotoxin to hematologic
References
malignancies. Semin Cancer Bio1 6:
297±306.
121 Kreitman RJ, Bailon P, Chaudhary
VK, FitzGerald DJP, Pastan I
(1994) Recombinant immunotoxins
containing anti-Tac(Fv) and derivatives
of Pseudomonas exotoxin produce complete
regression in mice of an interleukin-2
receptor-expressing human carcinoma.
Blood 83: 426±34.
122 Kreitman RJ,Wilson WH,Whie JD,
et al. (2000) Phase I trial of recombinant
immunotoxin anti-tac(Fv)±PE38 (LMB-
2) in patients with hematological malignancies.
J Clin Oncol 18: 1622±36.
123 Kreitman RJ,Wilson WH, Robbins D,
et al. (1999) Responses in refractory
hairy cell leukemia to a recombinant
immunotoxin. Blood 94: 3340±8.
124 Mavroudis OA, Jiang YZ, Hensel N,
et al. (1996) Specific depletion of alloreactivity
against haplotype mismatched related
individuals: a new approach to
graft-versus-host disease prophylaxis in
haploidentical bone marrow transplantation.
Bone Marrow Transplant 17: 793±9.
125 Engert A, Oiehl V, Schnell R, et al.
(1997) A phase-1 study of an anti-CD25
ricin A-chain immunotoxin (RFT5±
SMPT±dgA) in patients with refractory
Hodgkin's lymphoma. Blood 89: 403±
410.
126 Schnell R,Vitetta E, Schindler J,
et al. (1998) Clinical trials with an anti-
CD25 ricin A-chain experimental and
immunotoxin (RFT5±SMPT±dgA) in
Hodgkin's lymphoma. Leuk Lymph 30:
525±37.
127 Montagna O,Yvon E, Calcaterra V,
et al. (1999) Depletion of alloreactive T
cells by a specific anti-interleukin-2 receptor
p55 chain immunotoxin does
not impair in vitro antileukemia and
antiviral activity. Blood 93. 3550±7.
128 Kreitman RJ,Wyndham H, Bergeron
K, et al. (2001) Efficacy of the anti-
CD22 recombinant immunotoxin BL22
in chemotherapy-resistant hairy cell
leukemia. N Engl J Med 345: 241±7.
129 Amlot PL, Stone ML, Cunningham D,
et al. (1993) A phase I study of an anti-
CD22±deglycosylated ricin A chain immunotoxin
in the treatment of B-cell
375